Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
Nat Commun. 2023 Oct 23;14(1):6724.
doi: 10.1038/s41467-023-42562-2.
1 Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany. othman.al-sawaf@uk-koeln.de.
2 Cancer Institute, University College London, London, UK. othman.al-sawaf@uk-koeln.de.
3 Francis Crick Institute, London, UK. othman.al-sawaf@uk-koeln.de.
4 Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
5 Genentech Inc., South San Francisco, CA, USA.
6 Roche Products Ltd, Welwyn Garden City, UK.
7 Hoffmann-la Roche, Mississauga, ON, Canada.
8 Department III of Internal Medicine, Ulm University, Ulm, Germany.
9 Department II of Internal Medicine, University of Schleswig Holstein, Kiel, Germany.
10 AbbVie Inc., North Chicago, IL, USA.
11 Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, University of Cologne, Cologne, Germany.
12 Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany. michael.hallek@uni-koeln.de.
13 Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany. kirsten.fischer@uk-koeln.de.